Effect of vitamin D3 supplementation on peripheral B cell differentiation and isotype switching in patients with multiple sclerosis

Multiple Sclerosis Journal

Volumn 17, Issue 12, 2011, Pages 1418-1423

  Knippenberg, Stephanie ^a,b   Smolders, Joost ^a,b   Thewissen, Mariëlle ^a   Peelen, Evelyn ^a,b   Tervaert, Jan Willem Cohen ^a   Hupperts, Raymond ^a,b   Damoiseaux, Jan ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sittard Geleen Heerlen   (Netherlands)

Author keywords

B cell; multiple sclerosis; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; B CELL ACTIVATING FACTOR; BETA INTERFERON; COLECALCIFEROL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE COUNT; MULTIPLE SCLEROSIS; NEPHELOMETRY; VITAMIN SUPPLEMENTATION; B LYMPHOCYTE; BLOOD; CELL DIFFERENTIATION; CYTOLOGY; DIET SUPPLEMENTATION; DRUG EFFECT; GENE REARRANGEMENT; IMMUNOLOGY; STANDARD;

ADULT; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; CELL DIFFERENTIATION; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; MULTIPLE SCLEROSIS;

EID: 80054942142     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511412655     Document Type: Article

References (40)

1. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol. 2010 ; 9: 599-612
2. Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol. 2008 ; 194: 7-17
3. Simpson S, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010 ; 68: 193-203
4. Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler. 2008 ; 14: 1220-1224
5. van der Mei IA, Ponsonby AL, Dwyer T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol. 2007 ; 254: 581-590 (Pubitemid 46781963)
6. Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain. 2009 ; 132: 1146-1160
7. Smolders J, Thewissen M, Peelen E, et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One. 2009 ; 4: e6635
8. Burton JM, Kimball S, Vieth R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010 ; 74: 1852-1859
9. Smolders J, Peelen E, Thewissen M, et al. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One. 2010 ; 5: e15235
10. Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol. 2008 ; 4: 557-567
11. Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F. B cells and multiple sclerosis. Lancet Neurol. 2008 ; 7: 852-858
12. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 ; 358: 676-688 (Pubitemid 351240747)
13. Hedegaard CJ, Sellebjerg F, Krakauer M, Hesse D, Bendtzen K, Nielsen CH. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production. Mult Scler. 2010 ;:
14. Chen S, Sims GP, Chen XX, Gu YY, Lipsky PE. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol. 2007 ; 179: 1634-1647
15. Chen WC, Vayuvegula B, Gupta S. 1,25-Dihydroxyvitamin D3-mediated inhibition of human B cell differentiation. Clin Exp Immunol. 1987 ; 69: 639-646 (Pubitemid 17125569)
16. Iho S, Takahashi T, Kura F, Sugiyama H, Hoshino T. The effect of 1,25-dihydroxyvitamin D3 on in vitro immunoglobulin production in human B cells. J Immunol. 1986 ; 136: 4427-4431 (Pubitemid 16090656)
17. Lemire JM, Adams JS, Sakai R, Jordan SC. 1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest. 1984 ; 74: 657-661 (Pubitemid 14054016)
18. Agematsu K, Hokibara S, Nagumo H, Komiyama A. CD27: a memory B-cell marker. Immunol Today. 2000 ; 21: 204-206 (Pubitemid 30259022)
19. Pascual V, Liu YJ, Magalski A, de Bouteiller O, Banchereau J, Capra JD. Analysis of somatic mutation in five B cell subsets of human tonsil. J Exp Med. 1994 ; 180: 329-339 (Pubitemid 24181081)
20. Kabat EA, Glusman M, Knaub V. Quantitative estimation of the albumin and gamma globulin in normal and pathologic cerebrospinal fluid by immunochemical methods. Am J Med. 1948 ; 4: 653-662
21. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004 ; 14: 164-174 (Pubitemid 38656388)
22. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses: a trigger of T-cell-mediated disease in MS?. Ann Neurol. 2010 ; 67: 452-461
23. Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol. 2007 ; 178: 6092-6099 (Pubitemid 46717389)
24. Binard A, Le Pottier L, Devauchelle-Pensec V, Saraux A, Youinou P, Pers JO. Is the blood B-cell subset profile diagnostic for Sjögren syndrome?. Ann Rheum Dis. 2009 ; 68: 1447-1452
25. Sanz I, Wei C, Lee FE, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol. 2008 ; 20: 67-82
26. Youinou P, Renaudineau Y. The paradox of CD5-expressing B cells in systemic lupus erythematosus. Autoimmun Rev. 2007 ; 7: 149-154 (Pubitemid 350116728)
27. Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70. J Exp Med. 2011 ; 208: 67-80
28. Hirotani M, Niino M, Fukazawa T, et al. Decreased IL-10 production mediated by Toll-like receptor 9 in B cells in multiple sclerosis. J Neuroimmunol. 2010 ; 221: 95-100
29. Heine G, Niesner U, Chang HD, et al. 1,25-dihydroxyvitamin D(3) promotes IL-10 production in human B cells. Eur J Immunol. 2008 ; 38: 2210-2218
30. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science. 1983 ; 221: 1181-1183
31. Ho WY, Cooke MP, Goodnow CC, Davis MM. Resting and anergic B cells are defective in CD28-dependent costimulation of naive CD4+ T cells. J Exp Med. 1994 ; 179: 1539-1549 (Pubitemid 24129571)
32. Metlay JP, Pure E, Steinman RM. Control of the immune response at the level of antigen-presenting cells: a comparison of the function of dendritic cells and B lymphocytes. Adv Immunol. 1989 ; 47: 45-116 (Pubitemid 20010958)
33. Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol. 2005 ; 17: 282-289 (Pubitemid 40692663)
34. Krumbholz M, Theil D, Derfuss T, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med. 2005 ; 201: 195-200 (Pubitemid 40189428)
35. Huntington ND, Tomioka R, Clavarino C, et al. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol. 2006 ; 18: 1473-1485 (Pubitemid 44446825)
36. Krumbholz M, Faber H, Steinmeyer F, et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain. 2008 ; 131: 1455-1463 (Pubitemid 351806460)
37. Niino M, Hirotani M, Miyazaki Y, Sasaki H. Memory and naive B-cell subsets in patients with multiple sclerosis. Neurosci Lett. 2009 ; 464: 74-78
38. Ramgolam VS, Sha Y, Marcus KL, et al. B Cells as a Therapeutic Target for IFN-{beta} in Relapsing-Remitting Multiple Sclerosis. J Immunol. 2011 ; 186: 4518-4526
39. Smolders J, Hupperts R, Barkhof F, Grimaldi L, Holmoy T, Killestein J, et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing -remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a phase 2, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci. 2011 ;:
40. Vogt MH, ten Kate J, Drent RJ, Polman CH, Hupperts R. Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. Mult Scler. 2010 ; 16: 443-449